North America Acute Pancreatitis Market Forecast to 2030 - Regional Analysis - by Offerings, Causes, and End User

The North America acute pancreatitis market was valued at US$ 3,209.63 million in 2022 and is expected to reach US$ 5,000.71 million by 2030; it is estimated to grow at a CAGR of 5.7% from 2022 to 2030.

Rise in Pancreatic Cancer Cases Due to Acute Pancreatitis Fuels the North America Acute Pancreatitis Market

Pancreatic cancer is the fourth leading cause of cancer-related mortality in Western countries. According to the American Cancer Society, Cancer Facts & Figures 2022, the mortality rate of pancreatic cancer is predicted to be the second highest among all cancer-led mortality rates in the US by 2030. It is more likely to progress if not detected early when the tumor is resectable. According to an article published in the National Library of Medicine in 2021, only ~15% of pancreatic tumors are resectable at diagnosis, limiting five-year survival to 8%. However, the lack of early symptoms results in poor diagnosis and low resectability of these tumors. Acute pancreatitis may cause pancreatic cancer as it is an early symptom of pancreatic cancer, nearly 1% of acute pancreatitis admissions result in pancreatic cancer diagnoses. It takes several months for these patients to be diagnosed with pancreatic cancer after acute pancreatitis is diagnosed, but some suffer longer diagnostic delays due to initial misdiagnosis, which may hinder their recovery. Recurrent occurrence of acute pancreatitis leads to chronic pancreatitis, which may further increase the risk of pancreatic cancer.

According to the National Institute of Diabetes and Digestive and Kidney Diseases, acute pancreatitis leads to ~275,000 hospital admissions each year, and this number has been increasing in the US. ~35-40% of acute pancreatitis cases in the US are due to gallstones, while alcohol consumption is the cause of 30% of cases. Pancreatitis is usually mild in 80% of patients who are admitted, and most can be discharged within a few days of their hospitalization. Acute pancreatitis is associated with a mortality rate of ~2% and has a relapse rate between 0.6% and 5.6%. Alcohol-related pancreatitis has the highest rate of relapse. According to an article published in Lancet Gastroenterology Hepatology in 2022, the global pooled incidence of acute pancreatitis is 34 cases per 100,000 per year. North America has 58.2 cases per 100,000 people per year (the US has 58.2 cases per 100,000 people per year) while Europe has 24.7 and 15.0 cases per 100,000 people in Sweden and Denmark, respectively.

Acute pancreatitis, which causes the release of digestive enzymes into the pancreatic interstitial space instead of the pancreatic duct lumen, could be an early indicator of pancreatic cancer due to tumor obstruction of the pancreatic duct. Acute pancreatitis is a painful condition, so patients seek medical care sooner, which could lead to an early cancer diagnosis. Therefore, rising cases of pancreatic cancer due to acute pancreatitis boosts the growth of the North America acute pancreatitis market.

North America Acute Pancreatitis Market Overview

The North America acute pancreatitis market is segmented into the US, Canada, and Mexico. In 2022, the US held the largest market share in this region and is expected to continue its dominance during the forecast period. the North America acute pancreatitis market in North America is expected to grow due to the increasing burden of acute pancreatitis due to increase in cases of gallstones and excessive consumption of alcohol. Also, with an increase in technological advancement in healthcare facilities, the market in North America is expected to grow during the forecast period.

North America Acute Pancreatitis Market Revenue and Forecast to 2030 (US$ Mn)

North America Acute Pancreatitis Market Segmentation

The North America acute pancreatitis market is segmented offerings, causes, end user, and country.

Based on offerings, the North America acute pancreatitis market is segmented into medications, diagnosis, and others. The diagnosis segment held the largest market share in 2022.

Based on causes, the North America acute pancreatitis market is segmented into gallstones, alcoholism, genetic disorders, infection, and others. The gallstones segment held the largest market share in 2022.

Based on end user, the North America acute pancreatitis market is divided into hospitals, diagnostic laboratories, ambulatory surgical centres, and others. The hospitals segment held the largest market share in 2022.

Based on country, the North America acute pancreatitis market is segmented into the US, Canada, and Mexico. The US dominated the North America acute pancreatitis market share in 2022.

Abbott Laboratories, Baxter International Inc, Boston Scientific Corp, Dynavax Technologies Corp, Fresenius Kabi AG, GE HealthCare Technologies Inc, Koninklijke Philips NV, Medtronic Plc, and Samsung Healthcare are some of the leading companies operating in the North America acute pancreatitis market.

Reasons to Buy

• Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the North America acute pancreatitis market.
• Highlights key business priorities in order to assist companies to realign their business strategies.
• The key findings and recommendations highlight crucial progressive industry trends in North America acute pancreatitis market, thereby allowing players across the value chain to develop effective long-term strategies.
• Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
• Scrutinize in-depth North America market trends and outlook coupled with the factors driving the market, as well as those hindering it.
• Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing and distribution.